Product image of Glycopyrronium Bromide Accord (Glycopyrronium Bromide) supplied by GNH India

Glycopyrronium Bromide Accord

Active Ingredient:
Glycopyrronium Bromide
Origin:
EU

Glycopyrronium Bromide Accord (Glycopyrronium Bromide)

Glycopyrronium Bromide Accord is a prescription medication that contains the active ingredient glycopyrronium bromide and is supplied as an injectable solution for intramuscular or intravenous administration. It belongs to the anticholinergic (muscarinic antagonist) drug class and is marketed in the European Union for use under medical supervision.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glycopyrronium Bromide Accord is indicated for conditions where bronchodilation or reduction of secretions is required. It is commonly employed in the following clinical situations:

  • Management of acute bronchospasm associated with asthma or chronic obstructive pulmonary disease (COPD).
  • Maintenance therapy to improve airflow in patients with COPD.
  • Adjunct treatment for hyperhidrosis when other options are insufficient.
  • Peri‑operative reduction of airway secretions during anesthesia.
  • Off‑label use in certain cases of severe allergic reactions involving airway constriction.

Side Effects

Side effects of Glycopyrronium Bromide Accord vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common

  • Dry mouth
  • Throat irritation
  • Nasal dryness
  • Headache
  • Dizziness
  • Nausea

Serious

  • Severe tachycardia
  • Acute urinary retention
  • Angle‑closure glaucoma
  • Allergic skin reactions (rash, urticaria)
  • Respiratory distress due to paradoxical bronchospasm

Precautions & Warnings

Before initiating Glycopyrronium Bromide Accord, clinicians should consider several safety factors. Important precautions include:

  • Assessing for a history of glaucoma, especially narrow‑angle type.
  • Evaluating urinary tract disorders such as prostatic hypertrophy.
  • Monitoring cardiac function in patients with known arrhythmias.
  • Using caution in individuals with severe renal impairment.
  • Avoiding use in patients with known hypersensitivity to anticholinergic agents.
  • Adjusting dose or discontinuing if signs of paradoxical bronchospasm appear.

Avoid Interactions

Glycopyrronium Bromide Accord can interact with other medications, influencing its safety and efficacy. Interaction guidance is grouped as follows:

Avoid

  • Other anticholinergic drugs (e.g., ipratropium, atropine) due to additive antimuscarinic effects.
  • Beta‑blockers that may exacerbate bronchospasm.
  • Drugs that prolong QT interval in patients with cardiac risk.

Use with caution

  • Sympathomimetic agents (e.g., epinephrine) as they may increase heart rate.
  • Medications that affect renal clearance, such as certain diuretics.
  • Anesthetic agents that depress respiratory drive.
  • Oral antihistamines that have anticholinergic properties.

Frequently Asked Questions

Glycopyrronium Bromide Accord works as a competitive antagonist of muscarinic acetylcholine receptors, leading to bronchodilation and reduced airway secretions.

Yes, it may be administered intravenously or intramuscularly to relieve acute bronchospasm in asthma, but it should be used under medical supervision.

No, the product is supplied only as an injectable solution for intramuscular or intravenous use.

Common adverse effects include dry mouth, throat irritation, nasal dryness, headache, dizziness, and nausea.

It should be avoided in patients with known hypersensitivity to anticholinergic agents, narrow‑angle glaucoma, or severe urinary retention.

The drug can cause tachycardia, especially when used with other sympathomimetic agents, so cardiac monitoring may be required.

The pregnancy category is listed as unknown; therefore, it should be used only if the potential benefit justifies the potential risk to the fetus.

Combination with other anticholinergics like ipratropium is generally avoided due to additive antimuscarinic effects.

Monitoring should include respiratory status, heart rate, signs of urinary retention, and intra‑ocular pressure in at‑risk patients.

No, it is not classified as a controlled substance and is available by prescription only.

It belongs to the anticholinergic (muscarinic antagonist) class and is used as a bronchodilator.

Yes, it may be prescribed off‑label for severe hyperhidrosis when other treatments are ineffective.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.